Download by
Scanning QR Code
No Stock Yet
No Data
Bank of China Securities: dual-target drug use has become the future, it is recommended to pay attention to the company that already has double-resistance technology platform.
According to a research report issued by Bank of China Securities, bispecific antibodies can specifically combine two antigens or different epitopes of one antigen at the same time, and through their mode of action, they can achieve functions that monospecific antibodies cannot achieve, and are expected to solve potential problems such as single-target drug resistance and lack of safety. The overall research and development is too early, the international pharmaceutical giant has entered the bureau, and the domestic market has followed up quickly. It is recommended to pay attention to the companies that already have double-antibody technology platforms, such as Wuxi Biologics, Genscript Biotech Corporation, Kangfang Biological-B, Corning Jerry Pharmaceutical-B, and Platinum Pharmaceutical-B, Sino Biopharmaceutical.
Zhongsheng Pharmaceutical whose net profit fell by nearly 80% (01177): the success or failure is COVID-19 vaccine.
At the end of March this year, Zhongsheng Pharmaceutical released its 2021 annual report, in which the growth rate of net profit of more than 400 per cent became the biggest highlight of the company's financial report. As for the reason for the profit growth in the annual report, Zhongsheng Pharmaceutical specifically mentioned in its announcement that it was because "the financial performance of the associated company was strong, and the group's share of the profit and loss of the associated company and the joint venture company increased significantly compared with the same period last year." This associate is Sinovel Zhongwei, which took a stake in Zhongsheng Pharmaceutical at the end of 2020, and the profit of COVID-19 vaccine sales of the latter is included in the profit and loss of Zhongsheng Pharmaceutical's associate. However, "success or failure is also Xiao he." With the improvement of the coverage rate of COVID-19 vaccine in China, the market sales are gradually increasing.
Changes in Hong Kong stocks | after the performance of Zhongsheng Pharmaceutical (01177) fell by more than 6%, the first half's net profit decreased by 78% to 1.871 billion yuan compared with the same period last year.
Zhitong Financial APP learned that Sino Biopharmaceutical (01177) fell more than 6%. As of press time, it fell 5.82% to HK $4.21, with a turnover of HK $51.851 million. On the news side, Zhongsheng Pharmaceutical announced that during the six-month period ended June 30, 2022, due to the lower financial performance of an associate company than in the same period last year, the profit attributable to the group belonging to the parent company decreased by as much as 78% to about 1.871 billion yuan compared with the same period last year. The profit attributable to the joint venture decreased during the period, but the performance of the group's main business was in line with expectations and the performance grew steadily. According to the analysis, the associate refers to
Changes in Hong Kong stocks | Sino Biopharmaceutical fell 6.49%. It is expected that the net profit in the first half of the year will decrease by about 78% compared with the same period last year.
Sino Biopharmaceutical fell 6.49% to HK $4.18 on August 12th, with a total market capitalization of HK $78.6 billion. Sino Biopharmaceutical announced that during the six-month period ended June 30, 2022, due to the lower financial performance of an associate company than in the same period last year, the profits attributable to the group's parent company decreased by as much as 78% to about 1.871 billion yuan compared with the same period last year. During the period, the profit of the attributable associate decreased, but the performance of the group's main business was in line with expectations, and the performance grew steadily compared with the same period last year.
Hong Kong stock Sino Biopharmaceutical fell by more than 7%
Sino Biopharmaceutical fell nearly 4 per cent after it was announced that the profit of an associated company fell by as much as 78 per cent to about 1.871 billion yuan in the first half of the year because its financial performance was lower than the sam
The performance of the associated company was a drag, and pharmaceutical giant Sino Biopharmaceutical warned that the net profit in the first half of the year fell 78% compared with the same period last year.
Sino Biopharmaceutical (01177) expected medium-term net profit to be reduced by about 78% at most.
Zhitong Financial App News, Sino Biopharmaceutical (01177) issued an announcement that during the six-month period ended June 30, 2022, due to the lower financial performance of an associated company than in the same period last year, the profit attributable to the group belonging to the parent company decreased by about 78% to about 1.871 billion yuan compared with the same period last year. During the period, the profit of the attributable associate decreased, but the performance of the group's main business was in line with expectations, and the performance grew steadily compared with the same period last year.
Sino Biopharmaceutical: the net profit of homecoming in the first half of 2022 decreased 78% to 1.871 billion yuan compared with the same period last year.
Sino Biopharmaceutical: profit warning
Loading...
No Stock Yet